Buradasınız

FORMULATION, DEVELOPMENT AND OPTIMIZATION OF CONTROLLED POROSITY OSMOTIC PUMP TABLETS OF MILNACIPRAN HYDROCHLORIDE

Journal Name:

Publication Year:

Abstract (2. Language): 
Aim: To formulate, develop and optimize Controlled Porosity Osmotic Pump (CPOP) tablets of Milnacipran hydrochloride. Methodology: The CPOP tablet contains pore former i.e. water-soluble additive (PEG-8000) in the coating membrane which after coming in contact with water, dissolve, resulting in an in-situ formation of microporous structure. The plasma half-life of Milnacipran hydrochloride ranges from 6 to 8 hours and the dosage regimen is one 50 mg tablet twice a day. Hence, Milnacipran hydrochloride was chosen as a model drug with an aim to develop a controlled release system for 24 hours. The effect of different variables, like, ratio of drug to osmogent, % weight gain and level of pore former in the coating solution on the In Vitro drug release is studied using 23 factorial design. The effect of pH and agitation on drug release was also carried out. Drug-excipients compatibility was studied by Differential Scanning Calorimetry (DSC). Microporous structure of coating membrane of formulation was determined by Scanning Electron Microscope (SEM). Results: In Vitro dissolution studies revealed that drug release rate increased with the amount of osmogent because of increased water uptake, and hence increased driving force for drug release. Drug release was inversely proportional to membrane weight gain: however, directly related to the concentration of pore former in the membrane. Conclusion: Optimized formulation (SP7) was found to deliver 99.68 % of drug at a zero order rate in 24 hours.
FULL TEXT (PDF): 
239-259

REFERENCES

References: 

1. Remington, The Science and Practice of Pharmacy, 21st edition, Chapter no.-47, 939¬948.
2. Dennis J. Cada, Terri L. Levien and Danial E. Baker: Milnacipran, Formulary Drug Reviews. 2009; 44(7): 604-618.
3. Savella [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc; January 2009.
4. Deepak Gondaliya and Kilambi Pundarikakshudu: The Fabrication and Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride. Pharmaceutical technology. 2003; 58-68.
5. Sapna N. Makhija and Pradeep R. Vavia: Controlled porosity osmotic pump-based controlled release systems of Pseudoephedrine-I. Cellulose acetate as a semi permeable membrane. Journal of Controlled Release. 2003; 89: 5-18
6. A. Martin: Physical pharmacy, 4th edition, Lippincott Williams and Wilkins. 1994; 116¬117.
7. G. Santus and R. W. Baker: Osmotic Drug Delivery: A Review of the Patent
ISSN: 2277-8713
IJPRBS
Literature", Journal of Controlled Release.
1995; 35(1):1-21.
8. Pfefer: WEP Osmotishe Umtersuchen, Leipzig, 1877.
9. N. S. Parmar, S. K. Vyas and N. K. Jain: Advanced in controlled and novel drug delivery", CBS publisher; 22-31.
10. Kaushal, Aditya and Garg Sanjay: An update on osmotic drug delivery patents", Pharmaceutical Technology. 2003; 27(8):32-
39.
11. Ajay Babu, M. Prasada Rao and Vijaya Ratna J: Controlled-Porosity Osmotic Pump Tablets-An Overview. Journal of Pharmaceutical Research & Health Care,
2010; 2(1):114-126.
12. Roger Rajewski A: Applicability of (SBE) 7m- (3-CD in controlled-porosity Osmotic pump tablets (OPTs). Int. J. Pharm. 2004; 286: 81-88.
13. http://www.accessdata.fda.gov/drugsat fda docs/nda/2009/022256s000 CDTLMe mo.pdf
Available Online At www.ijprbs.com
Research Article
Sanjay
Modi, IJPRBS, 2012; Volume 1(6): 239-259
ISSN: 2277-8713
IJPRBS
14. http://www.accessdata.fda.gov/scripts/ cder/dissolution/dsp SearchResults Dissolu tions.cfm
15. Gohel MC, Parikh RK and Shah NY: Osmotic Drug Delivery: An Update", Pharma info.net. 2009; 7: 2.
16. ICH Harmonized Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A (R2). Current step 4 version. 2003; 3: 8.
Available Online

Thank you for copying data from http://www.arastirmax.com